Zu diesem Instrument liegen derzeit keine aktuellen Daten vor.
Anlageziel LO Selection - NextGen BioTech Syst. Hdg GBP PA Fonds
The Sub-Fund invests primarily in equity securities or equity-related securities issued by companies worldwide (including Emerging Markets) exercising a prominent part of their business activities in the healthcare industry. The Investment Manager’s approach focuses on small and mid-cap biotechnology companies providing positive impact through disruptive, next generation innovations that can bring, among other things, better treatment solutions while lowering the financial burden for society.
Stammdaten
| Valor | 58644832 |
| ISIN | LU2265262266 |
| Fondsgesellschaft | Lombard Odier Funds |
| Kategorie | Branchen: Andere Sektoren |
| Währung | GBP |
| Mindestanlage | 3’356.10 |
| VL-fähig? | Nein |
| Thesaurierend/Ausschüttend | Thesaurierend |
| Fondsmanager | Jérôme Berton |
Aktuelle Daten
| Fondsnote | - |
| Aktueller Rücknahmepreis | 50.26 |
| Fondsvolumen | 256’702’623.30GBP |
| Total Expense Ratio (TER) | 2.20% |
Gebühren
| Verwaltungsgebühr | - |
| Depotbankgebühr | - |
| Rücknahmegebühr | - |
| Ausgabeaufschlag | - |
Basisdaten
| Auflagedatum | 14.01.2021 |
| Depotbank | CACEIS Bank, Luxembourg Branch |
| Zahlstelle | Bank Lombard Odier & Co AG |
| Domizil | Luxembourg |
| Geschäftsjahr | 30.09.2023 |
Performancedaten
| Veränderung Vortag | 0.96 GBP (1.95 %) |